BRAINTREE, Mass., May 8, 2018 /Tech Bulletin/ — Haemonetics Corporation (NYSE: HAE) today appointed Said Bolorforosh, Ph.D., Executive Vice President and Chief Technology Officer, effective May 21, 2018. He will report to Chris Simon, Haemonetics’ Chief Executive Officer.
In this newly-created role, Bolorforosh will lead the company’s innovation agenda and oversee research, development and medical and clinical affairs. He will also be responsible for developing technical capabilities and optimizing product and technology investments to drive accelerated growth.
“We are committed to invigorating our product portfolio by advancing technologies that will improve donor and patient care as we pivot to the accelerated growth phase of our turnaround,” said Simon. “Said has diverse hands-on experiences translating customer needs to platform-based solutions as both a P&L leader and a head of technology. We are pleased to welcome him to Haemonetics as we continue to drive our value creation strategies.”
Prior to joining Haemonetics, Bolorforosh was President, Ultrasound, at Siemens Healthcare, where he delivered positive growth and market share gains by rebuilding the product portfolio, improving sales and distribution capabilities and optimizing go-to-market strategies globally. He previously served as Vice President and General Manager of Intensive Insulin Delivery, Vice President of R&D and Chief Technology Officer for Medtronic’s Diabetes division, leading P&L as well as technology and product development. From 2004 to 2014, Bolorforosh held positions of increasing responsibility at General Electric’s Ultrasound division, including Global General Manager, Growth and Strategy; Global General Manager, Point of Care; and Chief Technology Officer.
“I am excited to join Haemonetics and support the Company’s growth plans by driving innovation and leveraging new technologies in critical areas of health care,” said Bolorforosh.
Bolorforosh received a Bachelor of Science in Electronic and Electrical Engineering from Cardiff University, University of Wales, and a doctorate in Electronic Engineering from University of London, King’s College London. He holds numerous patents and publications.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
SOURCE Haemonetics Corporation